VKH
CRVS icon

Virtu KCG Holdings’s Corvus Pharmaceuticals CRVS Stock Holding History

Virtu KCG Holdings’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$213K Buy
+17,606
New +$188K 0.01% 2094

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtu KCG Holdings's CRVS Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2017: 17,606 shares worth $213K. The stake represents 0.01% of the portfolio and ranks #2094 among its holdings.

52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Virtu KCG Holdings held 17,606 shares of Corvus Pharmaceuticals worth $213K as of Q2 2017.
  • Corvus Pharmaceuticals was a new Virtu KCG Holdings position in Q2 2017.
  • Corvus Pharmaceuticals made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2094 holding.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.